U.S. Markets closed

If You Had Bought Infinity Pharmaceuticals (NASDAQ:INFI) Stock Five Years Ago, You'd Be Sitting On A 93% Loss, Today

Simply Wall St
·3 min read

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) shareholders will doubtless be very grateful to see the share price up 31% in the last month. But will that heal all the wounds inflicted over 5 years of declines? Unlikely. Five years have seen the share price descend precipitously, down a full 93%. It's true that the recent bounce could signal the company is turning over a new leaf, but we are not so sure. The important question is if the business itself justifies a higher share price in the long term.

We really feel for shareholders in this scenario. It's a good reminder of the importance of diversification, and it's worth keeping in mind there's more to life than money, anyway.

View our latest analysis for Infinity Pharmaceuticals

Infinity Pharmaceuticals wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually expect strong revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

In the last five years Infinity Pharmaceuticals saw its revenue shrink by 62% per year. That's definitely a weaker result than most pre-profit companies report. So it's not altogether surprising to see the share price down 42% per year in the same time period. This kind of price performance makes us very wary, especially when combined with falling revenue. Of course, the poor performance could mean the market has been too severe selling down. That can happen.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

NasdaqGS:INFI Income Statement April 20th 2020
NasdaqGS:INFI Income Statement April 20th 2020

Take a more thorough look at Infinity Pharmaceuticals's financial health with this free report on its balance sheet.

A Different Perspective

We regret to report that Infinity Pharmaceuticals shareholders are down 38% for the year. Unfortunately, that's worse than the broader market decline of 0.8%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Unfortunately, longer term shareholders are suffering worse, given the loss of 42% doled out over the last five years. We would want clear information suggesting the company will grow, before taking the view that the share price will stabilize. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For example, we've discovered 6 warning signs for Infinity Pharmaceuticals (1 is significant!) that you should be aware of before investing here.

Of course Infinity Pharmaceuticals may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.